Neoadjuvant Immunotherapy Following Definitive Surgical Treatment for Locoregionally Advanced Head and Neck Cancer: Perioperative Complication and Surgical Outcomes
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Background and Objectives We analyzed surgical outcomes, perioperative complications,and mortality in head and neck squamous cell carcinoma (HNSCC) in patients who underwentcurative surgery following neoadjuvant immunotherapy. Subjects and Method The records of 36 HNSCC patients who underwent curative surgerywith neoadjuvant immunotherapy and 69 HNSCC patients who received neoadjuvant chemotherapywere analyzed. Results The average operation time was 315 minutes, and the average bleeding volume was167 cc. The average length of hospital stay was 21 days. When evaluating surgical margin status,we found 24 patients (66.6%) who exhibited a negative margin. We found no case wheresurgery was impossible due to progression of the lesion during neoadjuvant immunotherapy. Compared to the neoadjuvant chemotherapy group, neoadjuvant immunotherapy group showedacceptable perioperative safety and complication profile. The postoperative complication ratewas 19.4% in the neoadjuvant immunotherapy group and 13.0% in the neoadjuvant chemotherapygroup (p=0.386). There were no serious complications during the recovery period aftersurgery or instances of death due to complications. Conclusion In HNSCC patients, there was no increase in the incidence of complications ormortality related to curative surgery after neoadjuvant immunotherapy.
Abstract
Background and Objectives We analyzed surgical outcomes, perioperative complications,and mortality in head and neck squamous cell carcinoma (HNSCC) in patients who underwentcurative surgery following neoadjuvant immunotherapy. Subjects and Method The records of 36 HNSCC patients who underwent curative surgerywith neoadjuvant immunotherapy and 69 HNSCC patients who received neoadjuvant chemotherapywere analyzed. Results The average operation time was 315 minutes, and the average bleeding volume was167 cc. The average length of hospital stay was 21 days. When evaluating surgical margin status,we found 24 patients (66.6%) who exhibited a negative margin. We found no case wheresurgery was impossible due to progression of the lesion during neoadjuvant immunotherapy. Compared to the neoadjuvant chemotherapy group, neoadjuvant immunotherapy group showedacceptable perioperative safety and complication profile. The postoperative complication ratewas 19.4% in the neoadjuvant immunotherapy group and 13.0% in the neoadjuvant chemotherapygroup (p=0.386). There were no serious complications during the recovery period aftersurgery or instances of death due to complications. Conclusion In HNSCC patients, there was no increase in the incidence of complications ormortality related to curative surgery after neoadjuvant immunotherapy.
참고문헌 (17)
- Gutiérrez Calderón V, "Neoadjuvant immunotherapy in resectable head and neck cancer : Oral cavity carcinoma as a potential research model", Ther Adv Med Oncol, 13, pp.1758835920984061~ (2021)
- Moskovitz J, "Immunotherapy for head and neck squamous cell carcinoma", Curr Oncol Rep, 20(2), pp.22~ (2018)
- Yu G, "Neoadjuvant immunotherapy for resectable esophageal cancer : A protocol of meta-analysis", PLoS One, 16(6), pp.e0252829~ (2021)
- Ferris RL, "Neoadjuvant nivolumab for patients with resectable HPVpositive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial", J Immunother Cancer, 9(6), pp.e002568~ (2021)
- Forde PM, "Neoadjuvant PD-1 blockade in resectable lung cancer", N Engl J Med, 378(21), pp.1976~1986 (2018)
- Necchi A, "Pembrolizumab as neoadjuvant therapy before radical cystectomy in patients with muscle-invasive urothelial bladder carcinoma (PURE-01): An open-label, single-arm, phase II study", J Clin Oncol, 36(34), pp.3353~3360 (2018)
- Amaria RN, "Neoadjuvant immune checkpoint blockade in high-risk resectable melanoma", Nat Med, 24(11), pp.1649~1654 (2018)
- Topalian SL, "Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the CheckMate 358 trial", J Clin Oncol, 38(22), pp.2476~2487 (2020)
- Jie HB, "CTLA-4+ regulatory T cells increased in cetuximab-treated head and neck cancer patients suppress NK cell cytotoxicity and correlate with poor prognosis", Cancer Res, 75(11), pp.2200~2210 (2015)
- Jie HB, "Increased PD-1+ and TIM-3+ TILs during cetuximab therapy inversely correlate with response in head and neck cancer patients", Cancer Immunol Res, 5(5), pp.408~416 (2017)
- Kansy BA, "T cell receptor richness in peripheral blood increases after cetuximab therapy and correlates with therapeutic response", Oncoimmunology, 7(11), pp.e1494112~ (2018)
- Schoenfeld JD, "Neoadjuvant nivolumab or nivolumab plus ipilimumab in untreated oral cavity squamous cell carcinoma : A phase 2 openlabel randomized clinical trial", JAMA Oncol, 6(10), pp.1563~1570 (2020)
- Uppaluri R, "Neoadjuvant and adjuvant pembrolizumab in resectable locally advanced, human papillomavirus-unrelated head and neck cancer: A multicenter, phase II trial", Clin Cancer Res, 26(19), pp.5140~5152 (2020)
- Ferrarotto R, "Impact of neoadjuvant durvalumab with or without tremelimumab on CD8+ tumor lymphocyte density, safety, and efficacy in patients with oropharynx cancer: CIAO trial results", Clin Cancer Res, 26(13), pp.3211~3219 (2020)
- Park YM, "A clinical trial of combination neoadjuvant chemotherapy and transoral robotic surgery in patients with T3 and T4 laryngo-hypopharyngeal cancer", Ann Surg Oncol, 25(4), pp.864~871 (2018)
- Park YM, "A new clinical trial of neoadjuvant chemotherapy combined with transoral robotic surgery and customized adjuvant therapy for patients with T3 or T4 oropharyngeal cancer", Ann Surg Oncol, 24(11), pp.3424~3429 (2017)
- Bott MJ, "Safety and feasibility of lung resection after immunotherapy for metastatic or unresectable tumors", Ann Thorac Surg, 106(1), pp.178~183 (2018)